Molecular mechanisms of drug-induced thrombocytopenia

Current Opinion in Hematology

Volumn 8, Issue 5, 2001, Pages 294-298

  Burgess, Janette K ^a  

^a University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTIBODY; CARBIMAZOLE; CD31 ANTIGEN; EPITOPE; EPTIFIBATIDE; FC RECEPTOR; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; HEPARIN; HEPARINOID; IMMUNOGLOBULIN G; LAMIFIBAN; MONOCLONAL ANTIBODY; QUINIDINE; RANITIDINE; RIFAMPICIN; THROMBOCYTE FACTOR 4; TIROFIBAN; VITRONECTIN RECEPTOR;

ANTIBODY COMBINING SITE; CLINICAL TRIAL; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTIBODIES; ANTIGENS, CD31; EPITOPES; HEPARIN; HUMANS; MODELS, BIOLOGICAL; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA;

EID: 0034830889     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200109000-00005     Document Type: Review

References (39)

1. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia
2. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
3. Laboratory investigation of immune thrombocytopenia
4. Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis
5. Platelet binding of IgG from patients with heparin-induced thrombocytopenia
6. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
7. Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides
8. Heparin-induced thrombocytopenia: Molecular pathogenesis
9. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: Biological characteristics and effects on platelet activation
10. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: Platelet factor 4
11. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia
12. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation
13. Activation of Fc gamma RII induces tyrosine phosphorylation of multiple proteins including Fc gamma RII
14. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients
15. In vitro inhibition of heparin-induced platelet aggregation in plasma from patients with HIT by SR 121566, a newly developed Gp IIb/IIIa antagonist
16. FcγRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization and platelet aggregation
17. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies
18. Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia
19. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies
20. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies
21. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: Characterization of the epitopes
22. Platelet GPIIb-IIIa blockers
23. Role of integrin alpha(v)beta3 in vascular biology
24. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1
25. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors
26. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion
27. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: Case reports, review of the literature and implications for therapy
28. Acute profound thrombocytopenia following abciximab therapy
29. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa
30. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
31. Use of a monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angiplasty
32. Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998
33. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia
34. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody
35. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia
36. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease
37. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia
38. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa
39. Molecular characterization of quinine/quinidine drug-dependent antibody platelet interaction using monoclonal antibodies